Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Retinal Biologics Market Poised To Hit $49.03 Billion By 2030 With A 11.9% CAGR
The retinal biologics market has experienced swift expansion in recent years. Its value is projected to rise from $28.12 billion in 2025 to $31.28 billion in 2026, with a compound annual growth rate (CAGR) of 11.2%. The historical growth of this market can be attributed to the increasing prevalence of age-related macular degeneration, a rising diabetic population, the clinical success of monoclonal antibody therapies, growing ophthalmology healthcare expenditure, and improvements in diagnostic imaging technologies.
The retinal biologics market size is projected to experience substantial growth over the next few years. It is forecast to expand to $49.03 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is attributable to progress in retinal biologic drug delivery systems, the expansion of biologics in development for retinal diseases, the rising embrace of personalized ophthalmic therapies, improvements in ophthalmology infrastructure within emerging markets, and an increasing need for treatments with extended duration. Key trends anticipated in this period include the development of long-acting retinal biologic formulations, a surge in the adoption of anti-VEGF biologics, a transition towards less invasive intraocular therapies, a wider application of biologics for diabetic eye conditions, and the proliferation of specialty retina clinics.
Get A Free Sample Report With In-Depth Market Insights:
Retinal Biologics Market Growth Factors: What’s Supporting Expansion?
The increasing demand for personalized medicine is expected to stimulate the expansion of the retinal biologics market moving forward. Personalized medicine involves customizing medical treatment to an individual’s distinct genetic makeup, which offers more effective and accurate healthcare interventions. In the context of retinal biologics, personalized medicine is employed to tailor treatment strategies based on individual genetic and molecular profiles, thereby optimizing efficacy and minimizing adverse effects. As an illustration, in February 2024, data from the Personalised Medicine Coalition, a US-based hospital and healthcare organization, showed that the FDA granted approval to 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Therefore, the growing need for personalized medicine is a key driver for the retinal biologics market’s growth.
Retinal Biologics Market Segment Performance And Emerging Opportunities
The retinal biologics market covered in this report is segmented –
1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor
2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications
3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors
2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins
Retinal Biologics Market Industry Trends: What’s Reshaping Demand?
Key players in the retinal biologics market are concentrating on creating innovative solutions, including bispecific antibodies, aimed at boosting treatment effectiveness, minimizing retinal damage, and bettering visual results. These biologic therapies, known as bispecific antibodies, are engineered to concurrently address two distinct pathways contributing to disease progression, thereby delivering enhanced therapeutic advantages. As an illustration, in May 2023, the Switzerland-based healthcare firm F. Hoffmann-La Roche Ltd. disclosed that its supplemental biologics license application (sBLA) for Vabysmo (faricimab), intended for treating macular edema after retinal vein occlusion (RVO), had been accepted by the U.S. Food and Drug Administration. This acceptance stemmed from two Phase III trials demonstrating early and sustained visual enhancement with Vabysmo, successfully meeting the primary endpoint of non-inferiority compared to aflibercept. This particular product represents the initial bispecific antibody approved for ocular use in managing neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Additional research revealed no retinal blood vessel leakage in patients treated with Vabysmo, a finding contrasting with those treated with aflibercept.
Retinal Biologics Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the retinal biologics market are Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Spark Therapeutics Inc., Bayer AG, Santen Pharmaceutical Co. Ltd., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Alimera Sciences Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Aerie Pharmaceuticals Inc., Ocular Therapeutix Inc., Fidia Farmaceutici S.p.A, Roche Holding AG, Amgen Inc., Biogen Inc., Genentech Inc., Allergan PLC
View The Full Retinal Biologics Market Report:
Retinal Biologics Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the retinal biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
